SavedAdd your journal

Journals / Retina-Vitreus / 2014 / Cilt: 22 - Sayı: 3

The efficacy of treatment in eales’ disease

Eales hastalığında tedavinin etkinliği

Ramazan ÖZELCE
Haluk ESGİN
Pages
189–193
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Visual prognosis is poor in macular involvement.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To investigate the efficacy of treatment in Eales’ disease.
📊
Key Findings & Data:Material and Methods: Thirty-three eyes of 21 patients at least 11 months followed with a diagnosis of Eales’ disease be- tween 1990 to 2012 were retrospectively evaluated.
💡
Conclusion & Impact:Visual prognosis is poor in macular involvement.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To investigate the efficacy of treatment in Eales’ disease. Material and Methods: Thirty-three eyes of 21 patients at least 11 months followed with a diagnosis of Eales’ disease be- tween 1990 to 2012 were retrospectively evaluated. Demographic characteristics, presenting symptoms, examination find- ings and treatments were evaluated. Fourteen eyes were treated with laser photocoagulation and systemic steroid, 10 were treated with only laser photocoagulation and 3 were treated with only systemic steroid. Four eyes were observed without treatment and 2 eyes underwent pars plana vitrectomy due to vitreous hemorrhage. Results: The mean age was 36.7±15.7 (15-65). M/F ratio was 2.5. Mean follow-up duration was 84 (11-225) months. It was 57% bilateral. The most common (58.1%) presenting symptom was blurred vision. The most common ophthalmoscopic find- ings on admission; neovascularization 42%, vitreous hemorrhage 39% and intraretinal hemorrhage 36%. Twenty-one (88%) of 24 eyes treated with laser photocoagulation alone or in combination with systemic steroid were maintained or showed improved vision. Macular edema or epiretinal membrane was seen in 5 of 6 eyes with decreased visual acuity. Conclusion: Laser photocoagulation treatment of Eales’ disease provides a good visual prognosis. Visual prognosis is poor in macular involvement.

Özet

Amaç: Eales hastalığında tedavinin etkinliğini araştırmak. Gereç ve Yöntem: Kliniğimize 1990-2012 yılları arasında Eales hastalığı tanısıyla en az 11 ay takip edilen 21 hastanın 33 gözü geriye dönük olarak değerlendirildi. Hastaların demografik özellikleri, başvuru yakınmaları, muayene bulguları ve uygulanan tedaviler değerlendirildi. Ondört göze lazer fotokoagülasyon ve sistemik steroid tedavisi,10 göze sadece lazer fotokoagülasyon, 3 göze sadece sistemik steroid tedavisi, 2 göze ise çekilmeyen vitre içi kanama nedeniyle pars plana vit- rektomi uygulandı. 3 hastanın dört gözü ise tedavisiz izlendi. Bulgular: Olguların yaş ortalaması 36.7±15.7 (15-65) ve erkek/kadın oranı 15/6 idi. Ortalama takip süresi 84 (11-225) ay olup, 21 hastanın 12’sinde (%57) hastalık bilateral olarak görüldü. En sık başvuru yakınması bulanık görme idi (%58.1). Başvuru anındaki en sık oftalmoskopik bulgular, neovaskülarizasyon %42, vitre içi kanama %39 ve retina içi kanama %36 idi. Tek başına veya sistemik steroidle kombine olarak lazer fotokoagülasyon yapılan 24 gözden 21’inde (%88) görme keskinliğinin aynı kaldığı veya arttığı saptanırken, görme keskinliği azalan 6 gözden 5’inde maküla ödemi veya epiretinal membran bulunduğu izlendi. Sonuç: Eales hastalığında lazer fotokoagülasyon tedavisi ile iyi görsel prognoz sağlanmaktadır. Maküla tutulumunda ise görsel prognoz kötüleşmektedir.

🔖

Cite This Article

ÖZELCE, R., ESGİN, H. (2014). The efficacy of treatment in eales’ disease. Retina-Vitreus, Cilt: 22 - Sayı: 3, 189–193. https://ajindex.com/articles/308138

References (18)

  1. Das T, Pathengay A, Hussain N et al. Eales disease: Diagnosis and management. Eye 2010;24:472-82
  2. Atmaca LS, Gündüz K. Eales hastalığında klinik ve tedavi. T Klin J Ophthalmol 1993;2:71-9
  3. Saxena S, Kumar D. New Classification System-based Visual Outcome in Eales’ Disease. Indian J Ophthalmol 2007;55:267-9
  4. Sezgin B, Karabacak M, Yüksel B ve ark. Eales hastalığında klinik seyir ve laser tedavisinin etkinliği. SSK İzmir EAH Tıp Derg 2004;10:59-63
  5. Yalçınbayır Ö. Eales hastalığı. T Klin J Ophthalmol-Special Topics 2011;4:92-8
  6. Perentes Y, Chan CC, Bovey E et al. Massive vascular endo- thelium growth factor (VEGF) expression in Eales’ disease. Klin Monatsbl Augenheilkd 2002;219:311-4
  7. Biswas J, Sharma T, Gopal L et al. Eales Disease-An Update. 2002;47:197-214
  8. Küçükerdönmez C, Akova YA, Yılmaz G. Intravitreal injec- tion of bevacizumab in Eales disease. Ocular Immunology and Inflamation 2008;16:63-5
  9. Kumar A, Sinha S. Rapid regression of disc and retinal neo- vascularization in a case of Eales disease after intravitreal bevacizumab. Can J Ophthalmol 2007;42:335-6
  10. Ünlü N, Acar MA, Kocaoğlan H. Eales hastalığında görsel prognoz. Ret-Vit 2001;9:253-8
  11. Eldem B, Çuhadaroğlu H. Eales hastalığının klinik özellikleri ve tedavi sonuçları. T Oft Gaz 1990;20:269-73
  12. Atmaca LS, Batioglu F, Sonmez PA. A long-term follow-up of Eales’ disease. Ocular Immunology and Inflamation 2002;10:213-21
  13. Shanmugam MP, Badrinath SS, Gopal L et al. Long term visual results of vitrectomy for Eales disease complications. International Ophthalmology 1998,22:61-4
  14. Atmaca LS, İdil A, Gündüz K. Visualisation of the retinal vasculitis in Eales disease. Ocular Immunology and Inflamation 1993;1:41-8
  15. Benedit WL, Wagner P. Thromboangitis obliternas of the reti- nal vessels. Am J Med Sci 1940;199:296
  16. Pomonis E, Triantafillidis JK, Tjenaki M et al. Report of Eales disease and ulcerative colitis in the same patient. Am J Gas- troenterol 1992;87:1531-2
  17. Renie WA, Murphy RP, Anderson KC et al. The evaluation of patients with Eales disease. Retina 1983;3:243-8
  18. Das T, Biswas J, Kumar A et al. Eales disease. Indian J Oph- thalmol 1994;42:3-18.